761440-64-6

Basic information

• Product Name: 1-(3-Methoxy-4-nitrophenyl)piperidin-4-one
• Synonyms: 1-(3-Methoxy-4-nitrophenyl)piperidin-4-one
• CAS NO: 761440-64-6
• Molecular Formula: C₁₂H₁₄N₂O₄
• Molecular Weight: 250.25056
• EINECS: 1592732-453-0
• Mol File: 761440-64-6.mol

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: 1-(3-Methoxy-4-nitrophenyl)piperidin-4-one(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(3-Methoxy-4-nitrophenyl)piperidin-4-one(761440-64-6)
• EPA Substance Registry System: 1-(3-Methoxy-4-nitrophenyl)piperidin-4-one(761440-64-6)

Safety Data

• Hazardous Substances Data: 761440-64-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
1-(3-methoxy-4-nitrophenyl)piperidin-4-one is used as a building block for the synthesis of pharmaceuticals, contributing to the development of new drugs for a range of therapeutic applications. Its unique structure allows it to be a key intermediate in the creation of various medicinal compounds.
Used in Organic Synthesis:
In the field of organic synthesis, 1-(3-methoxy-4-nitrophenyl)piperidin-4-one serves as a valuable component for creating a variety of organic compounds. Its versatility in chemical reactions makes it an essential part of many synthesis processes.

Upstream product

• 448-19-1 4-fluoro-2-methoxy-1-nitrobenzene 
• 41979-39-9 4-piperidone hydrochloride 
• 761440-22-6 1-(3-methoxy-4-nitrophenyl)piperidin-4-ol 
• 5382-16-1 4-HYDROXYPIPERIDINE 
• 40064-34-4 4-piperidone monohydrochloride monohydrate 
• 446-36-6 5-fluoro-2-nitrophenol 

Downstream Products

• 761440-65-7 1-(1-(3-methoxy-4-nitrophenyl)piperidin-4-yl)-4-methylpiperazine 
• 1089279-90-2 1-(3-methoxy-4-nitrophenyl)-N,N-dimethylpiperidine-4-amine 
• 1089281-10-6 4-{1-[3-(methyloxy)-4-nitrophenyl]-4-piperidinyl}-2-piperazinone 
• 1089279-61-7 4-(1-(3-methoxy-4-nitrophenyl)piperidin-4-yl)piperazine 
• 1089279-66-2 tert-butyl 4-(1-(3-methoxy-4-nitrophenyl)piperidin-4-yl)piperazine-1-carboxylate 
• 761440-23-7 1-(3-methoxy-4-nitro-phenyl)-4-pyrrolidin-1-yl-piperidine 
• 761440-35-1 4-(1-(3-methoxy-4-nitrophenyl)piperidin-4-yl)morpholine 
• 761440-42-0 1-acetyl-4-{1-[3-(methyloxy)-4-nitrophenyl]-4-piperidinyl}piperazine 
• 1246532-92-2 1-[1-(3-methoxy-4-nitro-phenyl)-4-piperidyl]piperidin-3-ol 
• 1356962-95-2 N-cyclopropyl-1-(3-methoxy-4-nitrophenyl)piperidin-4-amine 
• 1097917-15-1 N-{2-methoxy-4-[4-(4-methylpiperazin-1-yl)-piperidin-1-yl]phenyl}-N′-[2-(propane-2-sulfonyl)phenyl]-1,3,5-triazine-2,4-diamine 
• 1089279-91-3 1-(4-amino-3-methoxyphenyl)-N,N-dimethylpiperidine-4-amine 

Relevant articles and documents

Synthesis method of Brigatinib intermediate

The invention discloses a synthesis method of a Brigatinib intermediate. The Brigatinib intermediate is 2-methoxy-4-(4-(4-methyl piperazine-1-yl) piperidine-1-yl) aniline (I). The synthesis method comprises the following steps: taking 5-fluoro-2-nitroanis

Substituted diaminopyrimidine compound

The present invention provides a substituted diaminopyrimidine compound represented by a formula (I), or a pharmaceutically acceptable salt, a crystal form, a prodrug, a metabolite, a hydrate, a solvate, a stereoisomer or an isotope derivative thereof, as well as a pharmaceutical composition and uses thereof. The compound provided by the invention can be used for treating ALK-mediated related diseases, such as non-small cell lung cancer, breast cancer, neural tumor, esophageal cancer, soft tissue cancer, lymphoma and leukemia.

Preparation method and crystal form of deuterated diphenyl amino pyrimidine compound

The present invention discloses a preparation method and a crystal form of a compound shown in the formula (A) and also discloses a pharmaceutical composition comprising the crystal form of the compound shown in the formula (A) and a method for treating A

DEUTERIUM-MODIFIED BRIGATINIB DERIVATIVES, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, AND USE THEREOF

The present invention relates to the field of pharmaceutical chemistry, and relates to a deuterium-modified Brigatinib derivative, preparation method thereof, pharmaceutical composition containing the same and the uses of the deuterium-modified Brigatinib derivative and the pharmaceutical composition thereof in preparing a medicament for treating the disease mediated by anaplastic lymphoma kinase. The deuterium-modified Brigatinib derivative of the present invention has an excellent inhibitory activity on anaplastic lymphoma kinase and has better pharmacodynamic or pharmacokinetic properties relative to Brigatinib.

2,4-dibasic miazines compound

The invention belongs to the field of medical chemistry, relates to a 2,4-dibasic miazines compound and specifically relates to a compound shown as formula (I) or a pharmaceutically acceptable salt thereof, a drug compound thereof and an application thereof in treating EGFR or/and ALK mediated diseases.

Diaminopyrimidine compound and composition containing same

The invention provides a diaminopyrimidine compound and a composition containing the same and discloses the diaminopyrimidine compound shown as in a formula (I) and a drug combination containing the compound or salt thereof acceptable in crystal form and

METHOD FOR PRODUCING DI(ARYLAMINO)ARYL COMPOUND, AND SYNTHETIC INTERMEDIATE THEREFOR

Provided is a method for producing a di(arylamino)aryl compound that has superior inhibitory activity against the kinase activities of EML4-ALK fusion protein and mutant EGFR protein and is useful as an active ingredient in pharmaceutical compositions for cancer treatment. The production method includes no purification step using silica gel column chromatography or no step possibly producing a mutagenic mesylate ester as a by-product, greatly improves overall yield, and is high yield and low cost and suitable for the industrial production of pharmaceutical products. Also provided is a synthetic intermediate that is useful in the production method.

CHEMICAL COMPOUNDS

The present invention relates to compounds of Formula (I) and/or Formula (Ia): and to their salts, pharmaceutical compositions, methods of use, and methods for their preparation. These compounds inhibit ALK kinase activity, and thus may be used for the tr

THIAZOLE SULFONAMIDE AND OXAZOLE SULFONAMIDE KINASE INHIBITORS

The present invention provides thiazole sulfonamide and oxazole sulfonamide compounds, compositions containing the same, as well as processes for the preparation and methods for their use as pharmaceutical agents

COMPOUNDS AND THERAPEUTIC USES THEREOF

The invention relates to compounds, pharmaceutical compositions, and uses thereof, including therapeutic uses thereof, such as methods useful for treating cancer.